NFE2L2 and renal cell adenocarcinoma: When primary RCC displayed Nrf2 gene mutation and the C/A or A/A genotype of rs6721961 at the Nrf2 promoter region, expression of Nrf2 was elevated and metastases showed a worse response to sequential vascular endothelial growth factor-targeting therapy, resulting in unfavorable survival.